While the anecdotal accounts are compelling, significant questions remain around how microdosing works, and how much of the reported benefits are due to pharmacological effects, rather than [...]
Will Australia legalise ecstasy and magic mushrooms to treat mental illness? Here’s why it’s still too soon
People who use drugs understand drugs and drug use in ways that are often different to the way knowledge of drug use is constructed within the dominant medico-legal discourse. Their experiences [...]
Dr Bright said Australia had the opportunity to “scale up”, with bigger trials ensuring more therapists were trained so when MDMA was given the green light in the US, the safety data [...]
There is increasing evidence that psychedelic-assisted psychotherapy is effective for a range of psychological conditions. There are likely numerous mechanisms of action that contribute to these [...]
Scientists believe the illegal drug MDMA, also known as ecstasy, has an untapped potential to treat post-traumatic stress disorder (PTSD). But they say plans to test the drug on war veterans in [...]
This presentation was delivered by PRISM Vice-President Dr Stephen Bright at a fundraising seminar and dinner held at The Melbourne Brain Centre, Parkville on 8th April 2016.
Dr Stephen Bright talks to The Psychedelia Podcast about the problems facing the psychedelic movement in Australia
Dr Stephen Bright, a Psychologist working at Curtin University discusses psychedelic therapy.
In September 2016 PRISM’s Vice President Dr Stephen Bright spoke at Beyond Psychedelics, a global multidisciplinary psychedelic forum held in Prague, Czech Republic.
A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research
Click here to listen: https://soundcloud.com/enpsychedelia/the-psychedelic-inquirer-prism-interview
Some drugs that have therapeutic benefits are banned because of emerging patterns of use that do not conform to dominant paradigms. Such policies are often driven by morality rather than evidence.
PRISM will be presenting a panel discussion at the 2013 Australian Professional Society on Alcohol and other Drugs Scientific Conference 24-27 November in Brisbane.